Payment overview · 2025
General Payments
$633.58
31 reported records · 17 companies
Healthcare provider profile · identity verified
Steven Albert Singer, MD
Allopathic & Osteopathic Physicians|Family Medicine · LITTLETON, CO · NPI 1922078229
Verified facts
What the public records show
CMS Open Payments records show Steven Albert Singer, MD received $633.58 in general payments during 2025 across 31 reported records.
PFIZER INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.03 | 24.1% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.73 | 11.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.14 | 8.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.90 | 7.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.72 | 7.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.55 | 6.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.80 | 4.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.62 | 3.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $23.04 | 3.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.94 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.07 | 3.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.02 | 3.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.71 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.17 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.81 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.08 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.25 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.58 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.13 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $135.13 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.55 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $49.90 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.72 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $30.80 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 435 | 132 |
| Lisinopril | Lisinopril | 302 | 86 |
| Losartan Potassium | Losartan Potassium | 248 | 71 |
| Omeprazole | Omeprazole | 226 | 68 |
| Simvastatin | Simvastatin | 216 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 61 |
| Metformin Hcl | Metformin Hcl | 180 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 153 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 34 |
| Alprazolam | Alprazolam | 148 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 38 |
| Gabapentin | Gabapentin | 126 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 36 |
| Allopurinol | Allopurinol | 120 | 36 |
| Lorazepam | Lorazepam | 119 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 34 |
| Eliquis | Apixaban | 115 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 25 |
| Furosemide | Furosemide | 112 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 32 |
| Tramadol Hcl | Tramadol Hcl | 105 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 20 |
| Diazepam | Diazepam | 93 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 47 |
| Celecoxib | Celecoxib | 72 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 15 |
| Spironolactone | Spironolactone | 70 | 17 |
| Meloxicam | Meloxicam | 66 | 22 |
| Cephalexin | Cephalexin | 64 | 40 |
| Ondansetron Odt | Ondansetron | 64 | 15 |
| Pregabalin | Pregabalin | 64 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 12 |
| Estradiol | Estradiol | 58 | 15 |
| Famotidine | Famotidine | 58 | 18 |
| Atenolol | Atenolol | 57 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 21 |
| Trazodone Hcl | Trazodone Hcl | 55 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 14 |
| Finasteride | Finasteride | 53 | 16 |
| Potassium Chloride | Potassium Chloride | 52 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 14 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 45 | suppressed |
| Clonazepam | Clonazepam | 45 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 18 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Xarelto | Rivaroxaban | 45 | 14 |
| Prednisone | Prednisone | 44 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 14 |
| Acyclovir | Acyclovir | 41 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Lovastatin | Lovastatin | 39 | 14 |
| Clarithromycin | Clarithromycin | 38 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Propranolol Hcl | Propranolol Hcl | 35 | 13 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 11 |
| Morphine Sulfate | Morphine Sulfate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Fentanyl | Fentanyl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 12 |
| Temazepam | Temazepam | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Alogliptin | Alogliptin Benzoate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.58 · 31 records | PFIZER INC. | AIRSUPRA, AREXVY, CAPVAXIVE, Flector, Fluad, Flucelvax, GARDASIL 9, GEMTESA, General - Therapies, KRYSTEXXA, Kerendia, Licart, MOUNJARO, NURTEC ODT, QULIPTA, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, Tirosint, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error